Komori
Astellas Pharma (4503) · RiskRestated

Concentration of Sales to a Small Number of Wholesalers in Japan

First written in FY2019. 8 of 9 entries say "Restated". Latest entry: FY2024-Q3.

9entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019 – FY2024-Q32019: 120192020: 220202021: 320212022: 120222023: 120232024: 1
Same theme, other companies
Concentration of sales receivables and credit risk among a small number of business partnersA theme 164 companies write about · 164 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2017: 10 of 65 companies on the "Worse" side.

12 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 164 companies compared. The sentences above are computed from all 164.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3RestatedAnnual report

    「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    日本の少数卸売業者への販売集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  2. FY2024-Q1RestatedAnnual report

    「During the three-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    日本の少数卸売業者への販売集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  3. FY2022-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    日本の少数卸売業者への販売集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  4. FY2022-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    日本の少数卸売業者への販売集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  5. FY2022-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    日本の少数卸売業者への販売集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。quantified/materializedは本引用上は該当しない。
  6. FY2021-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    日本の少数卸売業者への販売集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  7. FY2021-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    日本の少数卸売業者への販売集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  8. FY2020-Q3RestatedAnnual report

    「There were no newly arising business or other risks during the cumulative third-quarter period, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」

    日本の少数卸売業者への販売集中を含む既存の事業等のリスクについて、重要な変更がないと再確認している。
  9. FY2019First statedAnnual report

    「当社グループは日本において、他の製薬企業と同様、主に少数の卸売業者を通じて製品を販売しています。上位4社への売上高の合計は、日本における売上高の約80%を占めています。」

    日本の販売が少数の卸売業者に集中しており、上位4社で日本売上の約80%を占めるという信用リスク上の集中を開示している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.